PL2095822T3 - Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy - Google Patents

Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy

Info

Publication number
PL2095822T3
PL2095822T3 PL09007549T PL09007549T PL2095822T3 PL 2095822 T3 PL2095822 T3 PL 2095822T3 PL 09007549 T PL09007549 T PL 09007549T PL 09007549 T PL09007549 T PL 09007549T PL 2095822 T3 PL2095822 T3 PL 2095822T3
Authority
PL
Poland
Prior art keywords
peptides
growth factor
vascular endothelial
factor receptor
endothelial growth
Prior art date
Application number
PL09007549T
Other languages
English (en)
Inventor
Hideaki Tahara
Takuya Tsunoda
Masabumi Shibuya
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of PL2095822T3 publication Critical patent/PL2095822T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
PL09007549T 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy PL2095822T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65752705P 2005-02-28 2005-02-28
EP06714491A EP1855707B1 (en) 2005-02-28 2006-02-17 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
EP09007549.0A EP2095822B1 (en) 2005-02-28 2006-02-17 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Publications (1)

Publication Number Publication Date
PL2095822T3 true PL2095822T3 (pl) 2014-03-31

Family

ID=36581423

Family Applications (3)

Application Number Title Priority Date Filing Date
PL06714491T PL1855707T3 (pl) 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
PL10177960T PL2289533T3 (pl) 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
PL09007549T PL2095822T3 (pl) 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL06714491T PL1855707T3 (pl) 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
PL10177960T PL2289533T3 (pl) 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy

Country Status (10)

Country Link
US (4) US7919099B2 (pl)
EP (4) EP2095822B1 (pl)
JP (3) JP4931154B2 (pl)
CY (1) CY1112867T1 (pl)
DK (3) DK1855707T3 (pl)
ES (3) ES2435650T3 (pl)
PL (3) PL1855707T3 (pl)
PT (3) PT1855707E (pl)
SI (3) SI1855707T1 (pl)
WO (1) WO2006093030A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514084B2 (en) * 2002-09-12 2009-04-07 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
SG178793A1 (en) * 2007-02-16 2012-03-29 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2018212358A1 (ja) * 2017-05-19 2018-11-22 学校法人慶應義塾 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0418667A (ja) * 1989-07-05 1992-01-22 Tohoku Nippon Denki Software Kk 自動配送システム
JPH0350140A (ja) * 1989-07-18 1991-03-04 Seiko Epson Corp 分布屈折率レンズの製造方法
EP0694042B1 (en) 1993-03-25 2004-11-03 Merck & Co. Inc. Inhibitor of vascular endothelial cell growth factor
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
WO2002072627A2 (en) * 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
FI110549B (fi) 2001-06-29 2003-02-14 Nokia Corp Menetelmä ja järjestely liikkeen määrittämiseksi
US20030157101A1 (en) 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
WO2003050140A1 (fr) 2001-12-10 2003-06-19 Kyogo Itoh Antigenes tumoraux
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
JP2004018667A (ja) 2002-06-17 2004-01-22 National Institute Of Advanced Industrial & Technology 高分子化合物膜の表面における炭酸カルシウム被膜の製造方法
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
US7514084B2 (en) 2002-09-12 2009-04-07 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization

Also Published As

Publication number Publication date
HK1133601A1 (en) 2010-04-01
HK1110529A1 (en) 2008-07-18
DK1855707T3 (da) 2012-07-16
WO2006093030A1 (en) 2006-09-08
EP1855707B1 (en) 2012-04-04
ES2435650T3 (es) 2013-12-20
SI2095822T1 (sl) 2013-12-31
PL1855707T3 (pl) 2012-08-31
EP2289532A1 (en) 2011-03-02
JP4843095B2 (ja) 2011-12-21
EP1855707A1 (en) 2007-11-21
JP2012102105A (ja) 2012-05-31
JP5789820B2 (ja) 2015-10-07
JP4931154B2 (ja) 2012-05-16
US8663647B2 (en) 2014-03-04
US8257711B2 (en) 2012-09-04
DK2095822T3 (da) 2014-01-13
PT1855707E (pt) 2012-05-25
EP2095822B1 (en) 2013-10-16
ES2442294T3 (es) 2014-02-11
SI1855707T1 (sl) 2012-07-31
EP2289533A1 (en) 2011-03-02
US7919099B2 (en) 2011-04-05
JP2008531463A (ja) 2008-08-14
DK2289533T3 (da) 2013-12-02
ES2385396T3 (es) 2012-07-24
SI2289533T1 (sl) 2013-11-29
JP2010265269A (ja) 2010-11-25
EP2289533B1 (en) 2013-09-18
US20090214581A1 (en) 2009-08-27
HK1152873A1 (en) 2012-03-16
PT2289533E (pt) 2013-12-10
US20120294877A1 (en) 2012-11-22
CY1112867T1 (el) 2016-04-13
PL2289533T3 (pl) 2014-02-28
US20110250219A1 (en) 2011-10-13
EP2095822A1 (en) 2009-09-02
US20140186381A1 (en) 2014-07-03
PT2095822E (pt) 2013-12-09

Similar Documents

Publication Publication Date Title
PT1819358E (pt) Anticorpos contra o recetor-1 do factor de crescimento endotelial vascular
IL186959A0 (en) Peptides and pharmaceutical compositions containing the same
IL230645A (en) Antibodies against activin a or b and their use to promote bone growth
PT2272873E (pt) Anticorpos contra o receptor humano de um factor de crescimento i semelhante a insulina e as suas aplicações
GB2420499B (en) Spinal prostheses
IL182267A0 (en) Novel anthranilamide pyridinureas as vascular endothelial growth factor
GB0715736D0 (en) LI-Key/Antigenic epitope hybrid peptide vaccines
IL163699A0 (en) Endothelial cells derived from human embryonic stem cells
IL209967A0 (en) Cdca1 epitope peptides and vaccines containing the same
SI2095822T1 (sl) Peptidi epitopov, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja, in cepiva, ki vsebujejo te peptide
PL1838341T3 (pl) Kompozycja szczepionki obejmująca białko wiążące fibronektynę lub peptyd wiążący fibronektynę
AU304285S (en) Cosmetic container
IL210861A (en) Milk epitope peptides and vaccines containing them
ZA200801874B (en) Antigenic peptides and their use
EP1893233A4 (en) PEPTIDES AND THERAPEUTIC VACCINES
ZA200701496B (en) Post-foaming dental mousse and methods utilizing the same
GB0427301D0 (en) Bone support
ZA201104890B (en) Wdrpuh epitope peptides and vaccines containing the same
GB2417482B (en) Box or container support
ZA200800566B (en) Therapeutic peptides and vaccines
EP1881843A4 (en) KINASEPEPTIDES AND ANTIBODIES
PL1874712T3 (pl) Wytwarzanie jodku metylu znakowanego <sup>11</sup>C oraz radioligandu 11C GB67
GB0418390D0 (en) Pot handler & cane support
AU2003214396A1 (en) The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
GB0508752D0 (en) Plant and container support